Abstract:Abstract Objective: Endometrial cancer is a common gynecologic malignancy, yet carcinogenesis remains elusive. Evidence showed that aberrant genomic methylation profiling contributes to the development of endometrial cancer. G protein-coupled estrogen receptor (GPER1), a membrane-associated estrogen receptor, was reported to play a multifaceted role in tumors. Its function in endometrial cancer is little known. Here, we conducted an integrated analysis of RNA expression, DNA methylation, and somatic mutations data from TCGA to investigate GPER1 upstream regulator and its influence in endometrial cancer biological process. Methods: RNA-seq, DNA methylation, and clinical information of endometrial cancer (n=554) and normal control (n=33) were obtained from TCGA database. RNA-seq profiles of GPER1 low and high groups were analyzed by R 4.1.0 software. KEGG and GSEA based on GPER1 expression were conducted. Correlation analysis of GPER1 and genomic instability were displayed. G1, the GPER1 agonist, was added to observe cell viability and metastatic ability in vitro. DNA methylation data was analyzed. Results: GPER1 expression was decreased in endometrial cancer compared with normal tissues. GPER1 was associated with poor overall survival (HR=0.52, p=0.003) (Figure 1). Low expression group showed a more frequent mutation landscape, higher tumor mutation burden (TMB), and micro-satellite instability (MSI) (Figure 2). Several hypermethylation loci on GPER1 CpG island were revealed. Methylation status is negatively correlative to RNA expression of GPER1 (Figure 3). P-value <0.05 and log2FC >1.5, 473 up-regulated and 114 down-regulated genes were screened. Up-regulated DEGs enriched in the Estrogen signaling pathway, Endometrial cancer, wnt signaling pathway, etc. Down-regulated DEGs enriched in Cell cycle, p53 signaling pathway, etc. (Figure 4). GSEA analysis showed that GPER1 low expression group was enriched in several biological processes including cell cycle checkpoint, Recombinational repair, etc. G1 inhibited endometrial cancer cell growth in a dose-dependent manner, and reduced cell metastatic ability (Figure 5). Conclusions: GPER1 exhibited decreased expression in endometrial cancer and DNA hypermethylation in promoter CpG island locus. The low GPER1 expression group showed prominent genomic instability. GPER1 agonists inhibit endometrial cancer cell growth and metastasis, which may serve as a therapeutic target. Citation Format: Xuan Feng, Ting Huang, Boqiang Shen, Juan Hao, Jiaqi Wang, Yangyang Dong, Jingyi Zhou, Jianliu Wang. Integrative genomic analysis reveals hypermethylation triggered GPER1 loss is associated with genomic instability of endometrial cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5686.

The G-Protein-Coupled Estrogen Receptor Agonist G-1 Mediates Antitumor Effects by Activating Apoptosis Pathways and Regulating Migration and Invasion in Cervical Cancer Cells

The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines

The Putative G-protein Coupled Estrogen Receptor Agonist G-1 Suppresses Proliferation of Ovarian and Breast Cancer Cells in a GPER-independent Manner.

Activation of G-protein coupled estrogen receptor inhibits the proliferation of cervical cancer cells via sustained activation of ERK1/2.

G Protein-Coupled Estrogen Receptor 1 (GPER 1) Mediates Estrogen-Induced, Proliferation of Leiomyoma Cells.

G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival

The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization

Mir-130A-3p Promotes Cell Proliferation and Invasion by Targeting Estrogen Receptor Α and Androgen Receptor in Cervical Cancer.

Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals

GPER Agonist G1 Prevents Wnt-Induced JUN Upregulation in HT29 Colorectal Cancer Cells

GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT–Mediated EMT

Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors

G-1: New Potential Therapeutic Option for Ovarian Cancer

G-1 Inhibits Breast Cancer Cell Growth Via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly

Abstract 5686: Integrative Genomic Analysis Reveals Hypermethylation Triggered GPER1 Loss is Associated with Genomic Instability of Endometrial Cancer

GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer

Expression of HIF-1α and Genes Involved in Glucose Metabolism Is Increased in Cervical Cancer and HPV-16-Positive Cell Lines

The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells

Cytoplasmic Expression of G Protein-Coupled Estrogen Receptor 1 Correlates with Poor Postoperative Prognosis in Non-Small Cell Lung Cancer

The G protein-coupled estrogen receptor as a modulator of neoplastic transformation

Elevated Glucose-6-phosphate Dehydrogenase Expression in the Cervical Cancer Cases is Associated with the Cancerigenic Event of High-Risk Human Papillomaviruses